Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2026 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de serviceAcceptable Use
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to Reports
Fundraising

Arcellx

Arcellx Raises $125M in Series C

9000 Virginia Manor Road, Beltsville, MD 20705June 8, 20242 min read
Employees
200+

Arcellx Raises $125M in Series C


Arcellx has successfully raised $125M in a Series C at a $1.5B valuation led by Betta Pharmaceuticals, Ally Bridge Group, Frazier Healthcare Partners, EcoR1 Capital.


Company Overview


Arcellx is a Biotech company headquartered in 9000 Virginia Manor Road, Beltsville, MD 20705, founded in 2014 with 200+ employees.


Cell therapy company


Fundraising Details


  • Amount Raised: $125M
  • Round Type: Series C
  • Valuation: $1.5B
  • Date: 2024-06-08
  • Investors: Betta Pharmaceuticals, Ally Bridge Group, Frazier Healthcare Partners, EcoR1 Capital

About Arcellx


Cell therapy company The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 9000 Virginia Manor Road, Beltsville, MD 20705
  • Founded: 2014
  • Team Size: 200+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in Arcellx's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Arcellx's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $1.5B valuation marks an important milestone for Arcellx, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, Arcellx is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-06-08. For more information about Arcellx, visit their headquarters at 9000 Virginia Manor Road, Beltsville, MD 20705.

Company Info

Headquarters
9000 Virginia Manor Road, Beltsville, MD 20705
Founded
2014
Team Size
200+

Topics

Fundraising(2912)Series C(300)BiotechArcellx

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free